Skip to main content
Shionogi & Co.,Ltd. logo

Shionogi & Co.,Ltd. — Investor Relations & Filings

Ticker · 4507 ISIN · JP3347200002 LEI · 35380049VXDTHZI3DY35 T Manufacturing
Open in API
Filings indexed 73 across all filing types
Latest filing 2026-04-27 M&A Activity
Country JP Japan
Listing T 4507

About Shionogi & Co.,Ltd.

https://www.shionogi.com/global/en/

Shionogi & Co., Ltd. is a drug discovery-based pharmaceutical company that researches, develops, manufactures, and markets a portfolio of prescription drugs, over-the-counter (OTC) products, and diagnostic reagents. The company prioritizes addressing unmet medical needs, with a significant focus on infectious diseases, including antibiotics, HIV, influenza, and COVID-19. A key strategic area is the development of solutions to combat antimicrobial resistance (AMR). Historically, the company is known for the development of Crestor, a widely used statin. Shionogi aims to provide innovative products and services to improve global health outcomes.

Recent filings

Filing Released Lang Actions
訂正臨時報告書
M&A Activity Classification · 94% confidence The document is a 臨時報告書 (extraordinary/timely report) filed under the Financial Instruments and Exchange Act disclosing the absorption‐type merger of the wholly owned subsidiary Torii Pharmaceuticals by Shionogi & Co. It provides detailed merger terms, schedules, financial and corporate information about the merging parties. This is clearly an M&A announcement and fits the definition of M&A Activity (Code: TAR).
2026-04-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 161
2025-11-07 Japanese
半期報告書－第161期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Shionogi & Co., Ltd. with the Kanto Local Finance Bureau. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-11-07 Japanese
訂正臨時報告書
M&A Activity Classification · 100% confidence The document is a 'Temporary Report' (臨時報告書) filed by Shionogi & Co., Ltd. with the Kanto Local Finance Bureau. It details a corporate split (absorption-type company split) involving the acquisition of the pharmaceutical business of Japan Tobacco Inc. This type of filing is a standard regulatory disclosure in Japan for significant corporate events, such as M&A or business restructuring, which falls under the 'Regulatory Filings' category as it is a specific statutory filing that does not fit into the other specialized categories like 10-K or Earnings Release.
2025-09-25 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were made at the '第160回定時株主総会' (160th Annual General Meeting) held on June 18, 2025. The content details the resolutions passed, including dividend approval, amendments to the articles of association, and the election/remuneration of directors and audit committee members. This structure—reporting the results of an AGM—is characteristic of a filing that announces the outcome of a shareholder meeting. Since the document reports the *results* of the AGM, it aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, or potentially DVA (Declaration of Voting Results & Voting Rights Announcements). Given the comprehensive nature of reporting all resolutions and voting tallies, AGM-R is the most appropriate fit for official AGM outcome documentation in this context, although DVA is also highly relevant. I will select AGM-R as it covers the overall meeting outcome documentation.
2025-06-19 Japanese
内部統制報告書－第160期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document explicitly states in the header section (【提出書類】) that it is an "内部統制報告書" (Internal Control Report). The legal basis cited (金融商品取引法第24条の４の４第１項) corresponds to the requirement for management's assessment of internal controls over financial reporting in Japan. Section 1 confirms the responsibility for internal control over financial reporting based on established frameworks. Section 3 concludes that the internal control over financial reporting is deemed effective as of the end of the fiscal year. This document directly addresses the assessment of internal controls, which aligns best with the Audit Report / Information category (AR), as it is a formal report on internal control effectiveness, distinct from a full annual report (10-K) or a simple earnings release (ER). While 'AR' is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests', an internal control report fits within the scope of formal assurance/control reporting.
2025-06-19 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.